Hindsight is 20/20.
作者信息
Moffett Alexander T, Hollander Harry, Berkenblit Gail, McArthur Justin C, Manesh Reza
机构信息
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Medicine, University of California San Francisco, San Francisco, California.
出版信息
J Hosp Med. 2020 Apr 1;15(4):245-249. doi: 10.12788/jhm.3358. Epub 2020 Feb 11.
Abstract
摘要
相似文献
1
Hindsight is 20/20.
J Hosp Med. 2020 Apr 1;15(4):245-249. doi: 10.12788/jhm.3358. Epub 2020 Feb 11.
2
[Regarding the article: "Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort"].
Acta Med Port. 2014 Jul-Aug;27(4):409-10. Epub 2014 Aug 29.
3
Body weight-based natalizumab treatment in adult patients with multiple sclerosis.
J Neurol. 2015 Mar;262(3):781-2. doi: 10.1007/s00415-015-7655-1. Epub 2015 Feb 7.
4
Localized sporotrichosis during natalizumab treatment in Multiple Sclerosis.
Mult Scler Relat Disord. 2020 Jun;41:102029. doi: 10.1016/j.msard.2020.102029. Epub 2020 Feb 26.
5
Altering the course of disease in multiple sclerosis: many large steps forward.
Arq Neuropsiquiatr. 2015 Sep;73(9):731-2. doi: 10.1590/0004-282X20150123.
6
Dual diagnosis: rheumatoid arthritis and multiple sclerosis.
PM R. 2014 Jan;6(1):96-9. doi: 10.1016/j.pmrj.2013.08.608.
7
Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.
Neurology. 2017 Feb 14;88(7):711-713. doi: 10.1212/WNL.0000000000003604. Epub 2017 Jan 11.
8
Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program.
J Am Acad Dermatol. 2019 Mar;80(3):820-821. doi: 10.1016/j.jaad.2018.10.052. Epub 2018 Nov 3.
9
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Mult Scler Relat Disord. 2020 Sep;44:102250. doi: 10.1016/j.msard.2020.102250. Epub 2020 Jun 3.
10
Use of natalizumab in multiple sclerosis: current perspectives.
Expert Opin Biol Ther. 2016 Sep;16(9):1151-62. doi: 10.1080/14712598.2016.1213810. Epub 2016 Jul 27.
本文引用的文献
1
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
JAMA Neurol. 2019 May 1;76(5):536-541. doi: 10.1001/jamaneurol.2018.4905.
2
Multiple sclerosis.
Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23.
3
Multiple Sclerosis.
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
4
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
5
Evolving concepts in the treatment of relapsing multiple sclerosis.
Lancet. 2017 Apr 1;389(10076):1347-1356. doi: 10.1016/S0140-6736(16)32388-1. Epub 2016 Nov 24.
6
Diagnosis of multiple sclerosis: progress and challenges.
Lancet. 2017 Apr 1;389(10076):1336-1346. doi: 10.1016/S0140-6736(16)30959-X. Epub 2016 Nov 24.
7
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.
8
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.
9
Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.
Mult Scler Relat Disord. 2014 Mar;3(2):147-55. doi: 10.1016/j.msard.2013.07.001. Epub 2013 Jul 31.
10
MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18.
Zotero 插件